MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML
Open Access
- 1 July 2016
- journal article
- Published by Elsevier in Cell Reports
- Vol. 16 (2) , 498-507
Abstract
No abstract availableKeywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (01GS0448, A3, SFB 1074)
- Deutsche Forschungsgemeinschaft (01GS0448, A3, SFB 1074)
This publication has 42 references indexed in Scilit:
- Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trialHaematologica, 2015
- The role of HOX genes in normal hematopoiesis and acute leukemiaLeukemia, 2012
- CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signalingJournal of Clinical Investigation, 2012
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- HOX expression patterns identify a common signature for favorable AMLLeukemia, 2008
- Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesisGenes & Development, 2007
- Identification of novel functional TBP‐binding sites and general factor repertoiresThe EMBO Journal, 2007
- Hematopoietic Stem Cell Expansion and Distinct Myeloid Developmental Abnormalities in a Murine Model of the AML1 - ETO TranslocationMolecular and Cellular Biology, 2002
- Analysis of TALE superclass homeobox genes (MEIS, PBC, KNOX, Iroquois, TGIF) reveals a novel domain conserved between plants and animalsNucleic Acids Research, 1997
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976